•
Jun 30, 2020
Mersana Q2 2020 Earnings Report
Mersana reported its financial results for Q2 2020 and provided a business update.
Key Takeaways
Mersana Therapeutics reported having $291.4 million in cash, cash equivalents and marketable securities as of June 30, 2020. Net cash used in operating activities in the second quarter of 2020 was $15.9 million.
Demonstrated strong proof of concept with XMT-1536 in ovarian cancer patients.
Initiated patient enrollment in the Phase 1 dose escalation study for XMT-1592.
Progressed earlier programs into late-stage discovery.
Strengthened balance sheet.